Close
Nordic 9Nordic 9

4BIO Capital (investor - Private Equity)

United Kingdom 4biocapital.com
See something wrong or missing? Let us know
Offices:London

4BIO CAPITAL is a trade name of 4BIO Ventures Management Ltd, a venture capital and public equities investors from the UK.

Average round investment:43.23M USD
Average number per year:1.5
Distribution: 2025 (1)2023 (2)2022 (1)2020 (2)
Portfolio companies: Norway ActitheraUnited Kingdom ViaNautisUnited Kingdom Ascend Gene & Cell Therapies See the entire list
Mostly invests in: United Kingdom United Kingdom (2) Biotech (6)
See the entire list

Showing 3 of 6 tracked investments in:

You need an account to access this feature. Log in or create one from here.

Do you have a question? Talk to us.

Investors with similar profile to 4BIO Capital

Name Criteria
United States Illumina Ventures
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • Common investees countries: United Kingdom, France
  • Average number of deals per year: 1.7
  • Active last 12 months: Yes
Switzerland SkyViews Life Science
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Manufacturing
  • Similar business models: B2B
  • Common investees countries: United Kingdom, Switzerland, France
  • Average number of deals per year: 1.7
  • Active last 12 months: Yes
Singapore Clay Capital
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Manufacturing
  • Similar business models: B2B
  • Common investees countries: United Kingdom, France
  • Average number of deals per year: 1.5
  • Active last 12 months: Yes
United States Longitude Capital
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Manufacturing
  • Similar business models: B2B
  • Common investees countries: Switzerland, France
  • Average number of deals per year: 1.5
  • Active last 12 months: Yes
France Merieux Equity Partners
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Pharma, Manufacturing
  • Similar business models: B2B
  • Common investees countries: United Kingdom, France
  • Average number of deals per year: 1.8
  • Active last 12 months: Yes
United States Omega Funds
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Pharma, Manufacturing
  • Similar business models: B2B
  • Common investees countries: United Kingdom, Switzerland
  • Average number of deals per year: 1.8
  • Active last 12 months: Yes
Luxembourg Vesalius Biocapital Partners
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Pharma, Manufacturing
  • Similar business models: B2B
  • Common investees countries: Switzerland
  • Average number of deals per year: 1.8
  • Active last 12 months: Yes
Germany PS Capital
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Pharma, Manufacturing
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.5
  • Active last 12 months: Yes
United States Epidarex Capital
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Pharma, Manufacturing
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 2.0
  • Active last 12 months: Yes
United States What If Ventures
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Pharma, Manufacturing
  • Similar business models: B2B
  • Common investees countries: United Kingdom, Switzerland
  • Average number of deals per year: 1.3
  • Active last 12 months: Yes
Top